You are here

P&T® Journal contents for November 2004


Meeting Highlights
Dr. Prescott reviews advances in therapies for Alzheimer’s disease, Parkinson’s disease, autism, schizophrenia, methamphetamine addiction, and cognition in Down syndrome as well as a possible relationship between isotretinoin and depression.
Lawrence M. Prescott, PhD
The factors that influence physicians to prescribe novel first-in-class drugs and later follow-on (established) drugs are explored.
Harold E. Glass, PhD, and Bruce Rosenthal, MBA
Part 1: The Evolution
The authors discuss the origins of drug formularies and the changing role of P&T committees.
Sanjeev Balu, BPharm, MBA, Paul O’Connor, RPh, MBA, and F. Randy Vogenberg, RPh, PhD
The authors review a coagulation factor therapy for patients at risk for bleeding.
Thomas A. Ratko, PhD, Joseph P. Cummings, PhD, and Karl A. Matuszewski, MS, PharmD
Caregivers of pediatric patients with AOMT were more satisfied with ciprofloxacin/dexamethasone than ofloxacin in healing otorrhea.
Curtis Waycaster, PhD, Paul Cockrum, PharmD, Bradley Reese, MD, Brent Lanier, MD, and G. Michael Wall, PhD
The FDA has issued new labeling changes for efavirenz, rituximab, levothyroxine, zoledronic acid, infliximab, and some of the second-generation antidepressants.
Marvin M. Goldenberg, PhD, RPh, MS


David Nash, MD, MBA, presents some examples of cutting-edge, “disruptive” technology, which has the potential to turn current practice on its head.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses job satisfaction, productivity, and the qualities of successful supervisors, as perceived by employees, that can lead to a reduction of errors.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the debate surrounding the changing face of P&T committees and their increased authority with the advent of the new Medicare drug benefit plans.
Stephen Barlas
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.